« on: January 19, 2019, 06:51:43 am »
In addition, if these estradiol tests were immunoassay-based then the correct numbers may be lower.
I run both tests. My immunoassay comes back at 55, LC/MS/MS is 79. No AI, obviously.
That's quite an unusual result, and especially hard to explain if it's repeatable. One study found LC/MS/MS results were averaging half the values from immunoassays. Other studies have provided similar, if less dramatic results, with LC/MS/MS always averaging less than IA. The reason is simply that IA can respond to other molecules in addition to estradiol.
I have repeated it. Previous one was IA 49/LC 63. I have dozens of examples. I know a lot of people on TRT. Usually see very close, if not the same, with levels in the 20s. I'm told, by someone who runs both IA and LC equipment, that the LC equipment is more difficult to work with. She is a researcher for Pfizer and stated they typically repeat LC tests to confirm results. According to her, the IA methodology, while not able to pick up lower levels (so the test result reads <15), is more reliable.
So how do you decide which test method is correct? Or do you just monitor for changes? Although one third of my LC/MS/MS results have been completely wrong, the others were consistently 10-15% under the IA results, meaning I could accept them as probably right. I have been preaching for a while that the IA test is more reliable, but that it should be calibrated against the LC/MS/MS test.
I think that is reasonable. I am not using an AI. Any consideration of that should be based off of symptoms over a lab number. In the absence of unmanageable symptoms, I think they should be avoided. If I had to rely on a single test, I think it would be the IA due to consistency. A change in the number, correlated with symptoms, would be more important than the actual number.
This is what I believe, based on a little research, regarding the IA v LC/MS/MS issue:
The ECLIA test (aka immunoassay or IA) for E2 management is commonly used for those on TRT. It is not an incorrect test or a test for women, but simply one way to check estradiol levels. The other commonly utilized test is the LC/MS/MS method (aka liquid chromatography dual mass spectrometry, sensitive or ultrasensitive). It is the more expensive of the two. There are inherent advantages and disadvantages to each of these two methods. I have been fortunate to be able to speak with professionals who work with both methods. One is a PhD researcher for Pfizer and the other is a medical doctor at Quest. I’ll summarize their comments.
The ECLIA method is the more reliable of the two in terms of consistent results. The equipment is easier to operate thus accuracy is less reliant on the skill of the operator. If the same sample were to be tested twenty times, there would be very little, if any, difference in the results.
The ECLIA method is not as “sensitive” in that it will not pick up E2 levels below 15pg/mL. If your E2 level with this test is 1-14pg/mL, the reported result will be “<15”. Because of this, it is not recommended for menopausal women, men in whom very low levels of E2 are suspected, or children. In other words, if your levels are below 15pg/mL, and it is important to know if the level is 1 or 14pg/mL, you do not want this test. For us, this is likely moot, since if you are experiencing low E2 symptoms and your test comes back at <15, you have your answer. For a woman being treated with anti-estrogen therapy for breast cancer, it may be necessary to know if the E2 level is zero or fourteen because therapeutically, they want zero estrogen.
A disadvantage to IA testing is that it may pick up other steroid metabolites, which in men would be very low levels, but still could alter the result. Another potential disadvantage is that elevated levels of C-reactive protein (CRP) may elevate the result. CRP is elevated in serious infections, cancer, auto-immune diseases, like rheumatoid arthritis and other rheumatoid diseases, cardiovascular disease and morbid obesity. Even birth control pills could increase CRP. A normal CRP level is 0-5 to 10mg/L. In the referenced illnesses, CRP can go over 100, or even over 200mg/L. Unless battling one of these serious conditions, CRP interference is unlikely.
The LC/MS/MS method will pick up lower E2 levels and would be indicated in menopausal women and some men if very low E2 levels are suspected and it is desired to know exactly how low, children and the previously mentioned women on anti-estrogen therapy. It will not be influenced by elevated CRP levels or other steroid metabolites.
While some may believe the ECLIA test is for women, on the contrary, as it pertains to women on anti-estrogen therapy, such as breast cancer patients, the LC/MS/MS is the test for women as CRP levels are a consideration and it is necessary to know if the treatment has achieved an estrogen level of zero.
On the other side of the coin, LC/MS/MS equipment is “temperamental” (as stated by the PhD who operates both) and results are more likely to be inconsistent. Because of this, researchers will often run the same sample multiple times.
It is not clear if FDA approval is significant, but this appears on Quest’s lab reports: This test was developed, and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. This statement is on LabCorp’s results: This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration.
It is unlikely that any difference in the same sample run through both methods will be clinically significant. Estradiol must be evaluated, and it should be checked initially and ongoing after starting TRT. It obviously makes sense to use the same method throughout. Most important are previous history and symptoms related to low or high E2. Those are correlated with before and after lab results. Any estradiol management should not be utilized without symptoms confirmed by lab results.